🇺🇸 Emtricitabine / Tenofovir in United States
7,664 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 7,664
Most-reported reactions
- Foetal Exposure During Pregnancy — 1,940 reports (25.31%)
- Maternal Exposure During Pregnancy — 1,620 reports (21.14%)
- Abortion Spontaneous — 782 reports (10.2%)
- Drug Ineffective — 684 reports (8.92%)
- Death — 574 reports (7.49%)
- Osteoporosis — 472 reports (6.16%)
- Virologic Failure — 444 reports (5.79%)
- Drug Interaction — 438 reports (5.72%)
- Product Dose Omission Issue — 363 reports (4.74%)
- Hiv Infection — 347 reports (4.53%)
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is Emtricitabine / Tenofovir approved in United States?
Emtricitabine / Tenofovir does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Emtricitabine / Tenofovir in United States?
The Miriam Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.